Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12831879 | 0.76 | CASR (0.39) | GFPT1CASR | |
| SCHEMBL1769506 | 0.76 | ITGB3 (0.50) | GFPT1ITGB3ITGA2BPTGS1SLC7A11 | |
| SCHEMBL1769508 | 0.76 | ITGB3 (0.50) | GFPT1ITGB3ITGA2BPTGS1SLC7A11 | |
| SCHEMBL826937 | 0.73 | ANPEP (0.36) | GFPT1GSRPTGS1SLC7A11 | |
| SCHEMBL25406446 | 0.71 | EPHX1 (0.50) | GFPT1ITGB3ITGA2B | |
| SCHEMBL25406448 | 0.71 | EPHX1 (0.50) | GFPT1ITGB3ITGA2B | |
| SCHEMBL31524073 | 0.69 | CYP2D6 (0.50) | GFPT1CASRGSRPTGS1SLC7A11 | |
| SCHEMBL29382069 | 0.69 | GFPT1 (0.44) | GFPT1ITGB3ITGA2BCASR | |
| SCHEMBL25660435 | 0.69 | PTGS1 (0.41) | PTGS1SLC7A11 | |
| SCHEMBL10514319 | 0.69 | PTGS1 (0.41) | PTGS1SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2007079130-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | DNPEP, DDC, PTMS | GFPT1 66/4885ITGB3 1390/4885ITGA2B 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.